Table 5.

Impact of 150‐mg Elagolix QD for 12 Months or 200‐mg Elagolix BID for 3 Months on Proportion of Patients Who Met Criteria for Antiosteoporosis Treatment: All Patients and by Percentile of Postmenopausal BMD in the Absence of Elagolix Treatment

Age strata, years	All patients			Post‐menopausal BMD in the absence of elagolix treatment
				<25th percentile			25th to 75th percentile			>75th percentile
	Not treated with elagolix	Treated with elagolix	Difference	Not treated with elagolix	Treated with elagolix	Difference	Not treated with elagolix	Treated with elagolix	Difference	Not treated with elagolix	Treated with elagolix	Difference
150 mg QD for 12 months
Patients who met criteria for antiosteoporosis treatment, N (%)
50–59	21 (2.53%)	24 (2.89%)	3 (0.36%)	17 (8.29%)	20 (9.76%)	3 (1.46%)	4 (0.96%)	4 (0.96%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
60–69	70 (8.14%)	72 (8.37%)	2 (0.23%)	56 (26.17%)	58 (27.1%)	2 (0.93%)	14 (3.24%)	14 (3.24%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
70–79	241 (39.31%)	252 (41.11%)	11 (1.79%)	139 (90.85%)	143 (93.46%)	4 (2.61%)	97 (31.6%)	103 (33.55%)	6 (1.95%)	5 (3.27%)	6 (3.92%)	1 (0.65%)
200 mg QD for 3 months
Patients who met criteria for antiosteoporosis treatment, N (%)
50–59	21 (2.53%)	24 (2.89%)	3 (0.36%)	17 (8.29%)	20 (9.76%)	3 (1.46%)	4 (0.96%)	4 (0.96%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
60–69	70 (8.14%)	72 (8.37%)	2 (0.23%)	56 (26.17%)	58 (27.1%)	2 (0.93%)	14 (3.24%)	14 (3.24%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
70–79	241 (39.31%)	251 (40.95%)	10 (1.63%)	139 (90.85%)	143 (93.46%)	4 (2.61%)	97 (31.6%)	103 (33.55%)	6 (1.95%)	5 (3.27%)	5 (3.27%)	0 (0.00%)

Patients met the threshold to initiate antiosteoporosis treatment if their 10‐year predicted risk of hip fracture was ≥3% or 10‐year probability of major osteoporotic fracture was ≥20%.

BID = Twice daily; QD = once daily.